Plant Name: Magnolia salicifolia
Taxonomic Information:
Plant ID: NPO15294
Plant Latin Name: Magnolia salicifolia
Taxonomy Genus: Magnolia
Taxonomy Family: Magnoliaceae
Plant External Links:
NCBI TaxonomyDB:
3411
Plant-of-the-World-Online:
554831-1
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCM; KampoGeographical Distribution:
Japan; China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| PTPN1; | |
| MAPK1; | |
| PPARD; PPARA; PPARG; | |
| ALOX15; HSD17B10; ALDH1A1; USP2; | |
| MMP3; | |
| TP53; | |
| SLCO1B3; SLCO1B1; | |
| SERPINA6; MAPT; LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.076E-07 | 9.041E-04 | CYP1A2, CYP2A6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.077E-06 | 3.351E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 2.836E-06 | 5.123E-03 | PPARA, PPARG, TP53, USP2 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 3.059E-06 | 5.123E-03 | MAPT, PTPN1, TP53 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.351E-06 | 6.242E-03 | CYP1A2, CYP2A6, CYP3A4, PPARD, SERPINA6 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.104E-06 | 6.242E-03 | CYP1A2, CYP3A4 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.017E-05 | 7.379E-03 | PPARA, PPARG |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 1.524E-05 | 9.472E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 1.524E-05 | 9.472E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.524E-05 | 9.472E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008283; cell proliferation | GO:0048662; negative regulation of smooth muscle cell proliferation | 1.594E-05 | 9.472E-03 | PPARD, PPARG, TP53 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.697E-05 | 9.472E-03 | PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.981E-05 | 1.078E-02 | ALOX15, CYP1A2, CYP2A6, CYP3A4 |
| MF | GO:0005488; binding | GO:0097371; MDM2/MDM4 family protein binding | 2.132E-05 | 1.084E-02 | PPARA, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.733E-07 | 5.964E-05 | CYP2A6, CYP1A2, ALDH1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 3.073E-06 | 1.291E-04 | MAPK1, PPARG, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.073E-06 | 1.291E-04 | CYP1A2, ALOX15, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.296E-05 | 8.011E-04 | CYP2A6, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.086E-05 | 8.011E-04 | CYP2A6, CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 4.296E-05 | 8.011E-04 | PPARG, PPARA, PPARD |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.680E-05 | 8.011E-04 | SLCO1B1, SLCO1B3, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.201E-05 | 1.008E-03 | CYP2A6, CYP1A2, CYP3A4 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 3.507E-04 | 4.017E-03 | LMNA, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.758E-04 | 5.791E-03 | MAPK1, PPARG, TP53, PPARD |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 3.017E-04 | 3.801E-03 | MAPK1, PPARA, TP53 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 5.975E-04 | 5.791E-03 | MAPK1, MAPT, HSD17B10 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.019E-03 | 7.131E-03 | CYP2A6, CYP1A2, ALOX15, ALDH1A1, CYP3A4, HSD17B10 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 9.763E-04 | 7.131E-03 | MAPK1, PPARA, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 7.301E-04 | 6.393E-03 | MMP3, PPARG, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 7.610E-04 | 6.393E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.416E-03 | 8.697E-03 | MAPK1, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 1.989E-03 | 9.428E-03 | MAPK1, MAPT, TP53 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 9.483E-06 | 2.987E-04 | CYP2A6, CYP1A2 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.223E-03 | 8.107E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.467E-03 | 8.697E-03 | MAPK1, PPARD |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 9.577E-04 | 7.131E-03 | CYP2A6, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.903E-03 | 9.428E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.733E-03 | 9.428E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.961E-03 | 9.428E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.020E-03 | 9.428E-03 | MAPK1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.519E-03 | 8.697E-03 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; TP53; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; TP53; |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP3; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP3; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
